PIVKA-II-Based Model IDs Liver Cancer Risk in Hep C-Related Cirrhosis
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 5, 2024 -- Among patients with hepatitis C virus (HCV)-related cirrhosis with sustained virological response (SVR) to direct-acting antivirals (DAAs), a serum protein induced by vitamin K absence or antagonist-II (PIVKA-II)-based model is accurate for predicting hepatocellular carcinoma (HCC) risk, according to a study published online Nov. 21 in Alimentary Pharmacology & Therapeutics.
Gian Paolo Caviglia, Ph.D., from the University of Turin in Italy, and colleagues developed and validated a PIVKA-II-based model for HCC risk stratification in patients with HCV-related cirrhosis with SVR to DAAs. Data were included for 1,220 patients (Turin cohort, 531; Pisa cohort, 335; and Milan cohort, 354).
The researchers derived a model including PIVKA-II combined with age, sex, alanine transaminase, aspartate aminotransferase, gamma-glutamyl transferase, platelet count, albumin, and total bilirubin from the training cohort (Turin + Pisa), with a C-index of 0.72. The models showed a C-index of 0.71 in the validation cohort (Milan), with an area under the curve of 0.84 for identifying patients who developed HCC within 12 months of follow-up. The cumulative incidence of HCC was 2.7, 4.0, and 14.3 percent in the low-, medium-, and high-risk groups when the patients were categorized into three risk categories. In the low-risk group, no HCC occurred within three years of follow-up.
"Our model allowed the identification of patients at low risk of HCC development that may not need surveillance, reducing costs and harms from surveillance," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Prevalence of Alcohol-Related Liver Fibrosis More Than Doubled Over Last 20 Years
MONDAY, July 28, 2025 -- The prevalence of liver fibrosis has more than doubled over the last 20 years among heavy alcohol consumers, according to a research letter published...
Increased Liver Enzyme Levels Seen With Use of Cannabidiol in Adults
THURSDAY, July 10, 2025 -- Use of cannabidiol (CBD) within the range consumers are taking with unregulated CBD products is associated with increased liver enzyme levels, according...
Metabolic Dysfunction-Associated Steatotic Liver Disease Linked to Risk for Sudden Hearing Loss
FRIDAY, June 20, 2025 -- Among older adults, metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with increased risk for sudden sensorineural hearing...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.